John Freeman

1.7k total citations · 1 hit paper
46 papers, 1.3k citations indexed

About

John Freeman is a scholar working on Hematology, Clinical Psychology and Education. According to data from OpenAlex, John Freeman has authored 46 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Clinical Psychology and 9 papers in Education. Recurrent topics in John Freeman's work include Multiple Myeloma Research and Treatments (7 papers), Early Childhood Education and Development (7 papers) and Cancer Treatment and Pharmacology (4 papers). John Freeman is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Early Childhood Education and Development (7 papers) and Cancer Treatment and Pharmacology (4 papers). John Freeman collaborates with scholars based in Canada, United States and Switzerland. John Freeman's co-authors include Oddrun Samdal, Mette Rasmussen, Christina Schnohr, Saoirse Nic Gabhainn, Ronald J. Iannotti, Chris Roberts, Robert Bwire, Igor Esnaola, Florence Houn and William Pickett and has published in prestigious journals such as Blood, PEDIATRICS and Gut.

In The Last Decade

John Freeman

45 papers receiving 1.2k citations

Hit Papers

The Health Behaviour in School-aged Children (HBSC) study... 2009 2026 2014 2020 2009 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Freeman Canada 16 317 300 299 270 267 46 1.3k
Raheem J. Paxton United States 28 265 0.8× 286 1.0× 383 1.3× 279 1.0× 82 0.3× 74 1.7k
Ladislav Csémy Czechia 16 723 2.3× 235 0.8× 236 0.8× 389 1.4× 149 0.6× 69 1.7k
Tess Gregory Australia 19 274 0.9× 181 0.6× 141 0.5× 178 0.7× 320 1.2× 53 1.1k
Catherine A. Lesesne United States 21 562 1.8× 208 0.7× 247 0.8× 597 2.2× 147 0.6× 45 1.8k
Anna Marriott United Kingdom 16 249 0.8× 117 0.4× 452 1.5× 213 0.8× 111 0.4× 42 1.5k
Lydia Gisle Belgium 15 388 1.2× 241 0.8× 288 1.0× 644 2.4× 146 0.5× 35 1.5k
Lisa Townsend United States 22 735 2.3× 327 1.1× 138 0.5× 182 0.7× 135 0.5× 56 1.4k
Sharon L. Ramey United States 18 581 1.8× 195 0.7× 163 0.5× 266 1.0× 335 1.3× 26 1.6k
Hang Lee United States 13 471 1.5× 191 0.6× 249 0.8× 800 3.0× 89 0.3× 21 2.9k
Alistair Campbell Australia 19 442 1.4× 209 0.7× 193 0.6× 241 0.9× 180 0.7× 54 1.2k

Countries citing papers authored by John Freeman

Since Specialization
Citations

This map shows the geographic impact of John Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Freeman more than expected).

Fields of papers citing papers by John Freeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Freeman. The network helps show where John Freeman may publish in the future.

Co-authorship network of co-authors of John Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of John Freeman. A scholar is included among the top collaborators of John Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Freeman. John Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strand, Natalie, et al.. (2024). Advances in radiofrequency ablation: mechanism of action and technology. Annals of Palliative Medicine. 13(4). 1028–1034. 7 indexed citations
2.
Chapman, Jennifer, et al.. (2020). Evaluating REMS Burden: A Comparative Time Analysis of 3 Channels for REMS Stakeholders to Perform Mandatory REMS Tasks. Therapeutic Innovation & Regulatory Science. 54(2). 318–323. 2 indexed citations
3.
Strand, Natalie, et al.. (2019). A rare complication of knee hematoma after genicular nerve radiofrequency ablation. PAIN Reports. 4(3). e736–e736. 9 indexed citations
4.
Marx, Robert, Emily E. Tanner‐Smith, Colleen Davison, et al.. (2017). Later school start times for supporting the education, health, and well‐being of high school students: a systematic review. Campbell Systematic Reviews. 13(1). 1–99. 10 indexed citations
6.
Esnaola, Igor, Víctor B. Arias, John Freeman, Yina Wang, & Benito Arias Martínez. (2017). Validity Evidence Based on Internal Structure of Scores of the Emotional Quotient Inventory: Youth Version Short (EQ-i: YV-S) in a Chinese Sample. Journal of Psychoeducational Assessment. 36(6). 576–587. 6 indexed citations
7.
Michaelson, Valerie, et al.. (2016). Inequalities in the spiritual health of young Canadians: a national, cross-sectional study. BMC Public Health. 16(1). 1200–1200. 17 indexed citations
8.
Esnaola, Igor, et al.. (2016). Validity Evidence based on Internal Structure of Scores of the Emotional Quotient-Inventory: Youth Version Short (EQ-i: YV-S) in a Spanish Sample. The Spanish Journal of Psychology. 19. E12–E12. 18 indexed citations
9.
Elgar, Frank J., Britt McKinnon, Sophie D. Walsh, et al.. (2015). Structural Determinants of Youth Bullying and Fighting in 79 Countries. Journal of Adolescent Health. 57(6). 643–650. 123 indexed citations
10.
Freeman, John, et al.. (2015). Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Therapeutics and Clinical Risk Management. 11. 1355–1355. 4 indexed citations
11.
Freeman, John, et al.. (2013). Teratogenic Drugs and Risk Management: An Implementation Assessment. Therapeutic Innovation & Regulatory Science. 48(4). 420–427. 4 indexed citations
12.
Felder-Puig, R., Robert Griebler, Oddrun Samdal, et al.. (2012). Does the School Performance Variable Used in the International Health Behavior in School‐Aged Children (HBSC) Study Reflect Students' School Grades?. Journal of School Health. 82(9). 404–409. 29 indexed citations
13.
White, Jonathan, et al.. (2011). Do H63D homozygote patients have clinically significant iron overload?: Table 1. Gut. 60(Suppl 1). A249.2–A250. 1 indexed citations
14.
Palumbo, Antonio, et al.. (2011). The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert Opinion on Drug Safety. 11(1). 107–120. 15 indexed citations
15.
Bwire, Robert, John Freeman, & Florence Houn. (2010). Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opinion on Drug Safety. 10(1). 3–8. 29 indexed citations
16.
Roberts, Chris, John Freeman, Oddrun Samdal, et al.. (2009). The Health Behaviour in School-aged Children (HBSC) study: methodological developments and current tensions. International Journal of Public Health. 54(S2). 140–150. 575 indexed citations breakdown →
17.
Shah, K., et al.. (2009). Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).. Blood. 114(22). 2881–2881. 1 indexed citations
18.
Brandenburg, Nancy A., et al.. (2009). Venous Thromboembolism in Myelodysplastic Syndrome Patients Receiving Lenalidomide. Clinical Drug Investigation. 29(3). 161–171. 22 indexed citations
19.
Castañeda, Carmen, et al.. (2008). RevAssist®. Drug Safety. 31(9). 743–752. 20 indexed citations
20.
Segal, Sydney, Walter R. Anyan, Sanford N. Cohen, et al.. (1980). Medroxyprogesterone Acetate (Depo-Provera). PEDIATRICS. 65(1). A74–A74. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026